AmgenAMGN
Oncology40 cited findings · profile updated 2026-08-20
440.90 USDnot live — refreshed daily
About Amgen
Amgen (AMGN) is an oncology research site with a portfolio that includes tarlatamab and BLINCYTO. Tarlatamab was studied in Study 20210004, where Grade 3+ TEAEs were observed in 54% of patients, compared to 80% in the Standard of Care arm. In the same study, Grade 3 CRS occurred in 1.2% of patients and Grade 3+ ICANS occurred in 1 patient.
BLINCYTO has been associated with various adverse reactions. In the BLINCYTO arm, adverse reactions of Grade 3 or higher incidence were 87%. Specific adverse events include pyrexia (any grade) at 91% and infusion related reaction (any grade) at 77%. Neurological toxicities of Grade 3 or higher incidence were 13%. Other notable safety findings for BLINCYTO include tremor (any grade) at 31% and headache (any grade) at 39%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Grade 3+ TEAEs (tarlatamab) | 54% | Amgen Inc. — Imdelltra FDA Review (NDA/BLA 761344, 2026), p.338 |
| Grade 3+ TEAEs (Standard of Care) | 80% | Amgen Inc. — Imdelltra FDA Review (NDA/BLA 761344, 2026), p.338 |
| Grade 3 CRS (tarlatamab) | 1.2% | Amgen Inc. — Imdelltra FDA Review (NDA/BLA 761344, 2026), p.338 |
| Adverse reactions of Grade 3 or higher incidence (BLINCYTO arm) | 87% | AMGEN — Blincyto FDA Review (NDA/BLA 125557, 2020), p.31 |
| Pyrexia incidence (any grade) (BLINCYTO) | 91% | AMGEN — Blincyto FDA Review (NDA/BLA 125557, 2020), p.29 |
| Grade 3 or higher neurological toxicities incidence (BLINCYTO) | 13% | AMGEN — Blincyto FDA Review (NDA/BLA 125557, 2020), p.66 |
Key projects
- tarlatamab
In Study 20210004, Grade 3+ TEAEs for tarlatamab were 54%.
- BLINCYTO
Adverse reactions of Grade 3 or higher incidence in the BLINCYTO arm were 87%.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →